NOP-Targeted Peptide Ligands.


Journal

Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231

Informations de publication

Date de publication:
2019
Historique:
pubmed: 29 1 2019
medline: 28 7 2019
entrez: 29 1 2019
Statut: ppublish

Résumé

The nociceptin/orphanin FQ (N/OFQ)-N/OFQ peptide (NOP) receptor system is widely distributed at both the peripheral and central level where it modulates important biological functions with increasing therapeutic implications. This chapter wants to provide a comprehensive and updated overview focused on the available structure-activity relationship studies on NOP receptor peptide ligands developed through different rational approaches. Punctual modifications and cyclizations of the N/OFQ sequence have been properly combined furnishing potent NOP selective ligands with different pharmacological activities (full and partial agonists, pure antagonists) and enhanced metabolic stability in vivo. The screening of peptide libraries provided a second family of NOP ligands that have been successfully optimized. Moreover, recent findings suggest the possibility to apply different multimerization strategies for the realization of multi-target NOP/opioid receptor ligands or tetrabranched N/OFQ derivatives with extraordinarily prolonged duration of action in vivo. The diverse approaches led to the identification of important pharmacological tools along with drug candidates currently in clinical development such as Rec 0438 (aka UFP-112) for the treatment of overactive bladder and SER 100 (aka ZP120) for the clinical management of systolic hypertension.

Identifiants

pubmed: 30689091
doi: 10.1007/164_2018_198
doi:

Substances chimiques

Ligands 0
Opioid Peptides 0
Receptors, Opioid 0

Types de publication

Journal Article

Langues

eng

Pagination

17-36

Auteurs

Delia Preti (D)

Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy.

Girolamo Caló (G)

Department of Medical Sciences, Section of Pharmacology, University of Ferrara and National Institute of Neurosciences, Ferrara, Italy.

Remo Guerrini (R)

Department of Chemical and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy. grm@unife.it.

Articles similaires

Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics
Proteins Protein Binding Ligands Internet Databases, Protein

Expanding the antiprotozoal activity and the mechanism of action of n-butyl and iso-butyl ester of quinoxaline-1,4-di-

Alonzo González-González, Oscar Sánchez-Sánchez, Lilián Yépez-Mulia et al.
1.00
Giardia lamblia Trichomonas vaginalis Entamoeba histolytica Antiprotozoal Agents Quinoxalines

Orientation-dependent CD45 inhibition with viral and engineered ligands.

Marta T Borowska, Liu D Liu, Nathanael A Caveney et al.
1.00
Leukocyte Common Antigens Humans Ligands T-Lymphocytes Viral Proteins

Classifications MeSH